MedTrace Logo

Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas

NCT04570683 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-09-30

No results posted yet for this study

Summary

The study aim is to assess the immunological and clinical response in basal cell carcinoma (BCC) treated with ablative fractionated laser (AFL) as monotherapy and compare with BCC treated with combination-therapy of AFL and the anti-PD1-drug nivolumab and with nivolumab as monotherapy.

Conditions

  • BCC - Basal Cell Carcinoma
  • Immune Response
  • Immunotherapy
  • Ablative Fractionated Laser

Interventions

DRUG

Nivolumab 10 MG/ML

Se previously

DEVICE

Ablative fractionated laser

Se previously

Sponsors & Collaborators

  • Bispebjerg Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-27
Primary Completion
2021-09-30
Completion
2021-11-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04570683 on ClinicalTrials.gov